Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing
Novo Nordisk parent's huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
According to a sneak peek of the data from one of Eli Lilly's (LLY 0.13%) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly ...
Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk
MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE: NVO). As the weight loss ma...
Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in t...
Is Novo Nordisk Stock a Buy?
Few companies garner as much reliable attention as Novo Nordisk (NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its...
Biotech funding has been an issue in the pharmaceutical industry, says Novo Holdings partner
Johan Hueffer, senior partner, principal investments at Novo Holdings, discusses investment in life sciences and his macro perspective.
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wedne...
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's domi...
Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. Management expects CagriSema to generate 25% weight loss after 68 w...
Ypsomed will make injection pens for Novo Nordisk's CagriSema, says source
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...
Are Dietary Drug Stocks Eli Lilly and Novo Nordisk Ready To Rise Again?
In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis...
Is Novo Nordisk Stock a Buy Right Now?
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong, with no signs of business deterioration. Despite Eli Lilly's underperformance in GLP-1 sales, Novo No...
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The ...
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
Related Companies